$100M to $250M is "sweet spot" for pharma venture funds

06/20/2013 | Genetic Engineering & Biotechnology News

Half of the 20 drugmaker venture capital funds on this list report total resources of between $100 million and $250 million. GlaxoSmithKline, Pfizer, Novartis, Sanofi, Merck and Boehringer Ingleheim are among the drugmakers starting or investing in venture capital funds for new drug discovery.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Assistant General Counsel, Regulatory
Cardinal Health
Waukegan, IL
Chief Executive Officer
UCare Minnesota
Minneapolis, MN